GlassScriptPhysician profile
Steven A Daniel
NPI 1063189884
$1,248.11
in general payments reported to CMS, 2019-2025
22 companies · $790 in 2025
The $790 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $458 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $160.00 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $134.55 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $115.91 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $99.67 | 2024-2025 | |
| Amgen INC. | $89.07 | 2024-2025 | Evenity, Repatha, Otezla |
| Inspire Medical Systems, INC. | $75.98 | 2024-2025 | Inspire |
| Abbvie INC. | $59.10 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $57.64 | 2024-2025 | Airsupra |
| Evoke Pharma, INC. | $53.73 | 2024 | |
| Exact Sciences Corporation | $52.74 | 2025 | Cologuard Collection Kit |
| Viiv Healthcare Company | $46.46 | 2025 | Apretude |
| Madrigal Pharmaceuticals | $45.39 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $41.99 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.64 | 2024-2025 | Jardiance |
| Eisai INC. | $33.97 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.39 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $27.72 | 2025 | |
| Dynavax Technologies Corporation | $25.02 | 2025 | Heplisav-B |
| Sanofi Pasteur INC. | $20.01 | 2025 | |
| Merck Sharp & Dohme LLC | $17.16 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Optinose US, INC. | $15.26 | 2024 | |
| Amneal Pharmaceuticals LLC | $13.71 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.